{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:11:38Z","timestamp":1790518298615,"version":"4.1.0"},"reference-count":31,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Int J Psychiatry Med"],"published-print":{"date-parts":[[2015,10]]},"abstract":"<jats:p>Inflammation-mediated changes in drug metabolism may lead to alterations in the absorption, distribution, and clearance of psychotropic drugs and thus elevate drug levels in blood and lead to intoxications. We report about two patients who developed an up to threefold increase of dose-related serum concentrations of risperidone\u2019s active moiety (risperidone plus 9-hydroxyrisperidone) during acute inflammation indicated by elevated C-reactive protein. The two female patients (aged 56 and 38 years, respectively) had the diagnoses of paranoid schizophrenia and schizoaffective disorder. For both patients, there was a close time-dependent parallel fluctuation of drug levels and C-reactive protein. Since elevated drug levels could not be attributed to prescribed comedications, it seemed likely that high-serum concentrations of risperidone were due to inflammation. It is concluded that elevated C-reactive protein should be considered as an indication to control blood levels of risperidone and possibly dose adaption.<\/jats:p>","DOI":"10.1177\/0091217415610313","type":"journal-article","created":{"date-parts":[[2015,10,8]],"date-time":"2015-10-08T20:48:42Z","timestamp":1444337322000},"page":"335-344","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":22,"title":["Elevated risperidone serum concentrations during acute inflammation, two cases"],"prefix":"10.1177","volume":"50","author":[{"given":"Gudrun","family":"Hefner","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, University Medical Center, Mainz, Germany"},{"name":"Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Falter","sequence":"additional","affiliation":[{"name":"Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Bruns","sequence":"additional","affiliation":[{"name":"Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Hiemke","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, University Medical Center, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2015,10,7]]},"reference":[{"key":"bibr1-0091217415610313","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1990.tb05280.x"},{"key":"bibr2-0091217415610313","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0022-3565(25)13416-2","volume":"247","author":"Leysen JE","year":"1988","journal-title":"J Pharmacol Exp Ther"},{"key":"bibr3-0091217415610313","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0022-3565(25)38596-4","volume":"268","author":"Roth BL","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"bibr4-0091217415610313","unstructured":"Risperdal\u00ae. Summary of product characteristics. Germany: Janssen-Cilag, December 2013."},{"key":"bibr5-0091217415610313","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g7337"},{"key":"bibr6-0091217415610313","doi-asserted-by":"publisher","DOI":"10.1007\/PL00005334"},{"key":"bibr7-0091217415610313","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-973836"},{"key":"bibr8-0091217415610313","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009347867"},{"key":"bibr9-0091217415610313","doi-asserted-by":"publisher","DOI":"10.1016\/S0033-3182(10)70664-2"},{"key":"bibr10-0091217415610313","doi-asserted-by":"publisher","DOI":"10.1586\/ern.12.138"},{"key":"bibr11-0091217415610313","doi-asserted-by":"publisher","DOI":"10.1055\/s-0031-1286287"},{"key":"bibr12-0091217415610313","doi-asserted-by":"publisher","DOI":"10.1007\/s002130000576"},{"key":"bibr13-0091217415610313","doi-asserted-by":"publisher","DOI":"10.1177\/0269881109104849"},{"key":"bibr14-0091217415610313","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2013.01.045"},{"key":"bibr15-0091217415610313","doi-asserted-by":"publisher","DOI":"10.1365\/s10337-007-0506-1"},{"key":"bibr16-0091217415610313","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2005.08.004"},{"key":"bibr17-0091217415610313","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(03)01034-9"},{"key":"bibr18-0091217415610313","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.1.4.629"},{"key":"bibr19-0091217415610313","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.46.120604.141059"},{"key":"bibr20-0091217415610313","doi-asserted-by":"publisher","DOI":"10.1124\/mi.7.2.10"},{"key":"bibr21-0091217415610313","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.107.018747"},{"key":"bibr22-0091217415610313","first-page":"207","volume":"29","author":"Morgan ET","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"bibr23-0091217415610313","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-7258(01)00165-6"},{"key":"bibr24-0091217415610313","doi-asserted-by":"publisher","DOI":"10.1081\/DMR-100101906"},{"key":"bibr25-0091217415610313","doi-asserted-by":"publisher","DOI":"10.2174\/1389200043335559"},{"key":"bibr26-0091217415610313","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181acd20b"},{"key":"bibr27-0091217415610313","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-002-0486-x"},{"key":"bibr28-0091217415610313","unstructured":"Flockhart DA. Drug interactions: cytochrome P450 drug interaction table. Indiana University School of Medicine, http:\/\/medicine.iupui.edu\/clinpharm\/ddis\/clinical-table\/ (2007, accessed 19 August 2014)."},{"key":"bibr29-0091217415610313","unstructured":"U.S. Food and Drug Administration. Drug development and drug interactions: table of substrates, inhibitors and inducers, http:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/DevelopmentResources\/DrugInteractionsLabeling\/ucm093664.htm (accessed 19 August 2014)."},{"key":"bibr30-0091217415610313","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.111.038679"},{"key":"bibr31-0091217415610313","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.4.10.1245"}],"container-title":["The International Journal of Psychiatry in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0091217415610313","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0091217415610313","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0091217415610313","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:14:23Z","timestamp":1777457663000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0091217415610313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["10.1177\/0091217415610313"],"URL":"https:\/\/doi.org\/10.1177\/0091217415610313","relation":{},"ISSN":["0091-2174","1541-3527"],"issn-type":[{"value":"0091-2174","type":"print"},{"value":"1541-3527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10]]}}}